sttcomp EBR FA longdeveloper of the world’s only wireless...

sttcomp EBR FA long

developer of the world’s only wireless cardiac pacing system for heart failure
Market cap $350m
As at 31 March US$7.7m cash + US$56.4m in short-term investments. Cash runway 18 months

EBR on track to submit the final module of its Pre-Market Approval (“PMA”) Application to the U.S. Food and Drug
Administration (“FDA”) in Q3 2024. The Company is targeting FDA approval in Q1 2025.
Stock is quite extremely illiquid
12 July CEO released a comprehensive update.
Seen the SP tick up
Initial TAM identified US$3.6b
Unique product and solution/unmet need